Company Encyclopedia
View More
name
Novartis AG
NOT.DE
News
View More

Novartis Reports Positive Phase III Results for Next-Generation Malaria Drug GanLum

Novartis AG has reported positive Phase III results for its next-generation malaria drug, GanLum (KLU156), developed with Medicines for Malaria Venture. The KALUMA study showed GanLum's cure rate at 97.4%, surpassing the 94.0% rate of the current standard treatment, artemether-lumefantrine. With plans to seek regulatory approvals, GanLum could be the first major innovation in malaria treatment in over 25 years. The results were officially announced by Novartis.

Reuters·
DE
NOT
0.00%
US
NVS
-0.49%
Reuters·
DE
NOT
0.00%
US
NVS
-0.49%

King Luther Capital Management Corp Buys 3,038 Shares of Novartis AG $NVS

King Luther Capital Management Corp increased its stake in Novartis AG by 27.4% in Q2, acquiring an additional 3,038 shares, bringing its total to 14,106 shares valued at $1.7 million. Other institutional investors also adjusted their positions. Analysts have mixed ratings on Novartis, with an average rating of "Hold" and a target price of $122.33. Novartis reported Q3 earnings of $2.25 EPS, slightly missing estimates, but revenue increased by 8.5% year-over-year to $13.91 billion.

Market Beat·
US
NVS
-0.49%
DE
NOT
0.00%
Market Beat·
US
NVS
-0.49%
DE
NOT
0.00%

Novartis Opens New Radioligand Therapy Facility in California

Novartis AG has opened a new 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California, marking its third RLT site in the US. This expansion is part of a $23 billion investment in US infrastructure over five years, which includes new facilities in Florida and Texas, and expansions in North Carolina, Indiana, and New Jersey. Additionally, Novartis plans to establish a biomedical research innovation hub in San Diego, emphasizing its commitment to enhancing cancer care and strengthening US operations.

Reuters·
US
NVS
-0.49%
DE
NOT
0.00%
Reuters·
US
NVS
-0.49%
DE
NOT
0.00%

Zevin Asset Management LLC Sells 2,173 Shares of Novartis AG $NVS

Zevin Asset Management LLC has reduced its stake in Novartis AG by 2.1%, selling 2,173 shares during the second quarter, leaving it with 99,336 shares valued at approximately $12 million. The firm ranks Novartis as its 24th largest holding. Other institutional investors have also adjusted their positions in Novartis. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and a price target of $122.33. Novartis recently reported earnings of $2.25 per share, slightly below expectations, with revenue of $13.91 billion, reflecting an 8.5% year-over-year increase.

Market Beat·
DE
NOT
0.00%
US
NVS
-0.49%
Market Beat·
DE
NOT
0.00%
US
NVS
-0.49%

Atlantic Union Bankshares Corp Grows Stock Holdings in Novartis AG $NVS

Atlantic Union Bankshares Corp increased its holdings in Novartis AG by 62.4% in Q2, owning 28,557 shares valued at $3.46 million. Other institutional investors also raised their stakes, with Dimensional Fund Advisors increasing by 5.2% and Goldman Sachs by 60.3%. Novartis shares opened at $126.71, with a market cap of $267.65 billion. The company reported Q3 earnings of $2.25 EPS, slightly missing estimates, but revenue rose 8.5% year-over-year. Analysts have mixed ratings on Novartis, with a consensus rating of "Hold" and an average target price of $122.33.

Market Beat·
DE
NOT
0.00%
US
AUB
+0.43%
Market Beat·
DE
NOT
0.00%
US
AUB
+0.43%